Work with me

I work as a biotech due diligence consultant for investors, angel groups and pharma business development, and in three related lines: commercialization assessments for universities and founders, operating jobs for early founders, and the research engine itself, run on a client's question. A due diligence consultant reads the primary record behind a company or an asset -- filings, trial registries, patents, the literature -- and tells the buyer where the record and the pitch disagree; weighing whether a gap is fatal or fixable stays with the buyer and the committee. Each engagement starts with your question and the decision it feeds, fixes the scope in writing before any work begins, and ends in a document where every figure sits two clicks from its source.

What you can hire

Examples of work

• Company due-diligence reads for a seed-stage angel group: two decks checked against the primary record, and two patents one deck called issued found expired.
• Conjugation technology landscape: workbook and board pack for a biotech operator.
• Early-stage investment workup: cap table, bottom-up market size, pricing, exit comparables, term-sheet redline, data-room punch list.
• Pre-registered clinical readout call with a price target and an invalidation level, sealed before the data.
• Briefing book answering a prospect's own questions: PDF, deck and tables.
• University invention commercialization assessment with an editable market model, benchmarked against a paid consultant.
• Target product profile, commercial and clinical-trial labels, device profile and pre-submission inputs for a surgical device, from 22 interviews with surgeons, nurses, patients and buyers, and a surgery observed.
• Seven oncology readouts called before the data and scored in public, misses included.
• Translation and verification of a government industry plan, every number and negation matched to the source characters.

How an engagement runs

One written answer to one question -- a screening read of a deck or an asset, a landscape of a field, a commercialization assessment of an invention -- with the recommendation on page one, the sections that carry the argument, a source ledger, and, where the question has numbers in it, the working model as a spreadsheet with every assumption named, so you can change one and watch the answer move.

You send the question and the decision it feeds. I return a written scope naming the question, the sources to be read, what you will receive and the delivery date, with the fee fixed against that scope. Nothing starts until you have agreed it in writing. I do not publish rates and I do not bill by the hour.

Two seed-stage decks went from received to both reads delivered in six days; a university invention went from signed CDA to delivered assessment and model in two days. Larger scopes carry their own date in the written scope.

I read the primary record -- filings, trial registries, patents, labels, the literature -- with a fleet of agents doing the reach across about 2,300 primary-database tools, a fact engine that admits a claim only with a verbatim source, an adversarial review by a model of a different lineage, and an audit gate before anything leaves.

One person reads every source and signs the call, so the document has one author who can defend any line in it, and no junior team sits between you and the answer. The reasoning is mine; the engine supplies the reach and the sources. The method is on the record: seven oncology readouts called before the data and scored in public, misses included, and about 100 reports produced by the same pipeline.

Investors' "four P's" -- people, process, philosophy, performance -- were written for choosing fund managers. For a biotech company or asset I ask four narrower questions: does the data show what the deck says, do the patents exist and still stand, who else is in the race, and what would the next readout have to show for the call to be right. The last one is written down and dated before the data lands.